Crizotinib (Xalkori; PF02341066)

Description: Crizotinib (formerly known as PF-02341066; trade name: Xalkori) is a potent, orally bioavailable small molecule inhibitor of c-Met and ALK with potential anticancer activity. It inhibits c-Met and ALK with IC50s of 11 nM and 24 nM in cell-based assays, respectively.

References: Cancer Res. 2007; 67(9):4408-17; Mol Cancer Ther. 2007; 6(12 Pt 1):3314-22; J Nucl Med. 2011; 52(8):1261-7.

Related CAS: 877399-52-5 (free base); 1415560-69-8 (HCl salt); 877399-53-6 (acetate); 1374356-45-2 (S)-crizotinib; 877397-65-4 (Crizotinib intermediate); 1415558-82-5 2-Keto Crizotinib (PF-06260182)

Chemical Name: (R)-3-(1-(2, 6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine

InChi Key: KTEIFNKAUNYNJU-GFCCVEGCSA-N

InChi Code: InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3, 8-12, 15, 26H, 4-7H2, 1H3, (H2, 25, 27)/t12-/m1/s1

SMILES Code: NC1=NC=C(C2=CN(C3CCNCC3)N=C2)C=C1O[CH](C4=C(Cl)C=CC(F)=C4Cl)C